The impact of MDR1 polymorphisms on prolactin concentrations in patients treated with risperidone.
Al Hadithy
Asmar F Y
AF
Wilffert
Bob
B
Bruggeman
Richard
R
Brouwers
Jacobus R B J
JR
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics*; D014150:Antipsychotic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011388:Prolactin / Q000097:blood* / Q000235:genetics; D018967:Risperidone / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy
C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D014150:Antipsychotic Agents; D011388:Prolactin; D018967:Risperidone